This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Mark Messier

Contributor

Mark Messier is the founder of BioRunUp.com. Messier is a Department of Justice-certified Criminal Intelligence Analyst and former IT professional, specializing in law-enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profits in four years. In April 2010, Messier founded the subscription-based stock-trading Web site BioRunUp.com to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

Mark Messier
By This Author:
« Back
Page 1 of 2

The Run-Up Trade: Biodel's Insulin Trial Results

By Mark Messier

Biodel shares should move higher ahead of insulin trial results in the third quarter.

08:00AM 05/30/13

Rockwell Medical Run-Up Trade Follows Financing

By Mark Messier

One trader believes Rockwell shares will rise into clinical trial results expected in July.

08:00AM 05/21/13

Synta Is Run-Up to ASCO Lung Cancer Data

By Mark Messier

The market overreacted to the resignation of Synta's R&D chief.

10:16AM 05/14/13

Expecting Ziopharm Shares To Run Into Phase III Data At Month's End

By Mark Messier

Ziopharm is an example of a stock with clinical trial results that can be traded realtively safely.

07:00AM 03/04/13

Run-Up Trade Into Dynavax's FDA Approval Decision

By Mark Messier

Three factors that will cause Dynavax shares to gain as get closer to the approval of its Hep B vaccine.

07:00AM 02/13/13

Titan Pharma: Run-Up Trade Into March FDA Panel

By Mark Messier

I expect traders will get an opportunity to profit from increased focus on Titan through March.

06:03AM 01/31/13

A.P. Pharma Run-Up Trade Into FDA Approval Decision

By Mark Messier

Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.

08:32AM 01/22/13

Shorting Alexza Pharma On FDA's Adasuve Approval

By Mark Messier

Alexza is setting up as a classic biotech run-down stock, says trader Mark Messier.

07:00AM 12/19/12

Anacor Pharma: Run-Up Trade Into January Trial Data

By Mark Messier

Anacor will be releasing phase III results for a toenail fungus drug in January.

08:29AM 12/11/12

Hyperion Shares Poised to Run Up Ahead of FDA Decision

By Mark Messier

FDA expected to issue approval decision on orphan drug Ravicti on Jan. 23.

08:00AM 12/05/12

« Back
Page 1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,551.32 +151.65 0.92%
S&P 500 1,930.59 +26.58 1.40%
NASDAQ 4,387.6680 +71.5940 1.66%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs